Table 5. Characteristics of carbapenemase-producing isolates of carbapenem-resistant Pseudomonas aeruginosa from incident cases, United States, July–October 2015.
| Isolate no. | Site | Carbapenemase | Carbapenemase gene location | ST | Antimicrobial resistance pattern* |
|---|---|---|---|---|---|
| 1 | New Mexico | IMP-18 | Plasmid | ST179 | AMK, CAZ, CAZ/AVI, CIP, DOR, FEP, GEN, IMI, LEV, MER, CEF/TAZ, TOB |
| 2 | New Mexico | VIM-2 | Chromosomal | ST308 | CAZ,† CAZ/AVI, CIP, DOR, GEN, IMI, LEV, MER, CEF/TAZ, TOB |
| 3 | Tennessee | HMB-2 | Chromosomal | ST235 | AMK, CAZ, CAZ/AVI, CIP, DOR, FEP, GEN, LEV, MER, PIP/TAZ, CEF/TAZ, TOB |
*Resistance pattern based on reference broth microdilution testing using 2019 Clinical and Laboratory Standards Institute interpretative criteria. AMK, amikacin; CAZ, ceftazidime; CAZ/AVI, ceftazidime/avibactam; CEF/TAZ, ceftolozane-tazobactam; CIP, ciprofloxacin; DOR, doripenem; FEP, cefepime; GEN, gentamicin; HMB, Hamburg metallo-β-lactamase; IMI, imipenem; IMP, active-on-imipenem; LEV, levofloxacin; MER, meropenem; PIP/TAZ, piperacillin/tazobactam; ST, sequence type; TOB, tobramycin; VIM, Verona integron mediated. †Intermediate antimicrobial susceptibility.